Allurion Gastric Balloon System
Allurion Technologies, Inc. · Decision date Feb 20, 2026
What did the FDA approve?
The FDA database record P250023 shows an approval decision dated 2026-02-20 for the Allurion Gastric Balloon System (AGBS), submitted by Allurion Technologies, Inc. under product code LTI, device category "IMPLANT, INTRAGASTRIC FOR MORBID OBESITY." The record lists no supplement type or supplement reason, so the fields supplied do not identify a prior PMA or establish any change from an earlier cleared scope; the decision is described only as an approval.
Per the source statement, the approved indication covers short-term limited weight loss in adults aged 22 to 65 years with BMI from 30 to 40 kg/m2 who have had at least one unsuccessful weight loss program attempt. The system is to be used with a moderate intensity lifestyle modification therapy program, consists of up to two Allurion Balloons placed during a 10-month period, and has a variable residence time averaging 15.3 weeks. This is the applicant's stated purpose, not independent evidence of safety or clinical effectiveness.
FDA approval order statement
Approval for the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) greater than or equal to 30 kg/m2 and less than or equal to 40 kg/m2 who have had at least one unsuccessful attempt at a weight loss program. The residence time for each AGBS is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Feb 20, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250023
- Regulatory pathway
- Premarket approval application
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- Decision code
- APPR
- Decision date
- Feb 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250023 received
Application receipt date recorded by FDA.
P250023 · FDA decision
APPR
P250023/S001 · Related supplement
Allurion Gastric Balloon System
P250023/S002 · Related supplement
Allurion Gastric Balloon System
Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Allurion Gastric Balloon SystemP250023/S001 | Allurion Technologies, Inc. | PMA supplement | Sep 9, 2026 | FDA |
Allurion Gastric Balloon SystemP250023/S002 | Allurion Technologies, Inc. | PMA supplement | Sep 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allurion Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11 Huron Dr., Natick, MA, 01760
Sources and methodology
- Original FDA record: P250023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
